Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;75(1):226-228.
doi: 10.1016/j.jhep.2021.01.036. Epub 2021 Feb 5.

Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients

Gwilym J Webb  1 , Andrew M Moon  2 , Eleanor Barnes  3 , A Sidney Barritt 4th  2 , Thomas Marjot  3
Affiliations
Comment

Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients

Gwilym J Webb et al. J Hepatol. 2021 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors have no other conflicts of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

Fig. 1
Fig. 1
Associations between age and comorbidity with death following SARS-CoV-2 infection in liver transplant patients. (A) Outcomes of multivariable logistic regression with backwards stepwise selection for retention in the model at p <0.1 with death as the dependent variable and the following independent variables: age, sex, Charlson comorbidity index (CCI; without age), hypertension, and baseline tacrolimus, ciclosporin, mycophenolate mofetil (MMF), everolimus, and corticosteroid use. SETH = cohort described by Colmenero et al; CH/SC = COVID-Hep/SECURE-Cirrhosis; combined represents the 2 cohorts combined. Within the SETH cohort, factors remaining significantly associated with death were age (odds ratio [OR] 3.47/10 years; 95% CI 1.50–8.00; p = 0.004) and CCI without age (1.29/point; 95% CI 1.00–1.67; p = 0.049). Within the COVID-Hep/SECURE-Cirrhosis cohort only age (OR 1.73/10 years; 95% CI 1.09–2.74; p = 0.02) remained significant. Within the combined cohort, age (1.95/10 years; 1.35–2.82; p <0.001) and CCI (OR 1.24; 95% CI 1.04–1.48; p = 0.014) remained significant. (B–D) Plots of age in years against CCI adjusted to exclude age and split by whether patients survived (blue circles) or died (red squares) following SARS-CoV-2 infection in (B) Spanish SETH cohort (n = 108 with complete data); (C) COVID-Hep/SECURE-Cirrhosis international cohort (n = 150); (D) COVID-Hep/SECURE-Cirrhosis comparison non-LT cohort from a single UK hospital network (n = 627). A single Spanish patient from the COVID-Hep/SECURE-Cirrhosis registries who could potentially have been included in the Spanish SETH registry was not included in the analysis. Asterisks for patients who died with CCI <3 (including points for age) in panel B denote additional at-risk cofactors: ∗concurrent influenza; ∗∗second liver transplant; ∗∗∗recurrent primary sclerosing cholangitis with jaundice at baseline; ∗∗∗∗baseline jaundice of unknown cause. Horizontal jitter has been added to the X axis. (This figure appears in color on the web.)
See this image and copyright information in PMC

Comment in

Comment on

  • Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients.
    Colmenero J, Rodríguez-Perálvarez M, Salcedo M, Arias-Milla A, Muñoz-Serrano A, Graus J, Nuño J, Gastaca M, Bustamante-Schneider J, Cachero A, Lladó L, Caballero A, Fernández-Yunquera A, Loinaz C, Fernández I, Fondevila C, Navasa M, Iñarrairaegui M, Castells L, Pascual S, Ramírez P, Vinaixa C, González-Dieguez ML, González-Grande R, Hierro L, Nogueras F, Otero A, Álamo JM, Blanco-Fernández G, Fábrega E, García-Pajares F, Montero JL, Tomé S, De la Rosa G, Pons JA. Colmenero J, et al. J Hepatol. 2021 Jan;74(1):148-155. doi: 10.1016/j.jhep.2020.07.040. Epub 2020 Aug 1. J Hepatol. 2021. PMID: 32750442 Free PMC article.

References

    1. Colmenero J., Rodríguez-Perálvarez M., Salcedo M., Arias-Milla A., Muñoz-Serrano A., Graus J., et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021 Jan;74(1):148–155. doi: 10.1016/j.jhep.2020.07.040. Epub 2020 Aug 1. PMID: 32750442; PMCID: PMC7395653. - DOI - PMC - PubMed
    1. Webb G.J., Marjot T., Cook J.A., Aloman C., Armstrong M.J., Brenner E.J., et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol. 2020 - PMC - PubMed
    1. Marjot T., Moon A.M., Cook J.A., Abd-Elsalam S., Aloman C., Armstrong M.J., et al. J Hepatol. 2020:1–42. doi: 10.1016/j.jhep.2020.09.024. - DOI - PubMed
    1. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. - PMC - PubMed
    1. Levin A.T., Cochran K.B., Walsh S.P. National Bureau of Economic Research; 2020. Assessing the age specificity of infection fatality rates for COVID-19: meta-analysis & public policy implications. Report No.: 0898-2937. - PMC - PubMed